Structural Genomics Consortium
The Structural Genomics Consortium (SGC) is a global public-private partnership founded in 2003, dedicated to accelerating drug discovery through open-access research. It comprises approximately 250 scientists across seven research sites worldwide, fostering collaboration between academia and industry. SGC's core mission is to understand the functions of all human proteins, making its research output freely accessible. Over two decades, they have determined thousands of protein structures and developed numerous chemical probes. Their current focus is on leveraging AI and machine learning to transform early drug discovery, with initiatives like Target 2035 aiming to develop chemical probes for every human protein by 2035. This approach supports research into various diseases including cancer, Alzheimer's, and Parkinson's.
Structural Genomics Consortium
The Structural Genomics Consortium (SGC) is a global public-private partnership founded in 2003, dedicated to accelerating drug discovery through open-access research. It comprises approximately 250 scientists across seven research sites worldwide, fostering collaboration between academia and industry. SGC's core mission is to understand the functions of all human proteins, making its research output freely accessible. Over two decades, they have determined thousands of protein structures and developed numerous chemical probes. Their current focus is on leveraging AI and machine learning to transform early drug discovery, with initiatives like Target 2035 aiming to develop chemical probes for every human protein by 2035. This approach supports research into various diseases including cancer, Alzheimer's, and Parkinson's.